GUBamy, AbbVie-licensed amylin drug from Gubra, shows 7.8% weight loss in Phase 1 trial, vs 2% weight gain with placebo after ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...

CagriSema is a combination of cagrilintide — a nascent form of weight loss treatment known as an amylin analog — and ...

Drug screening is the process by which potential drugs are identified and optimized before selection of a candidate drug to progress to clinical trials. It can involve screening large libraries of ...

Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.

Over the course of the operation, authorities said they seized 400 grams of powdered cocaine; three AR-15-style assault rifles; multiple magazines and assorted ammunition; scales and drug packaging ...

Justice minister says drug consumption rooms, where users can safely inject, would be a step forward. As the president tries to force Mexico to stop the flow of drugs, cartel members tell Quentin ...

Roche is in-licensing co-development and co-commercialization rights to Denmark’s Zealand Pharma’s long-acting amylin analog, petrelintide, being developed in phase IIb studies for people who ...

Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 billion with Denmark’s Zealand Pharma to co-develop its lead obesity ...

Before Roche, U.S. AbbVie also announced its entry into the obesity drug market using amylin analogs on the 4th. The company has signed a license agreement for the obesity drug candidate ...